Bethesda, MD, United States
Bethesda, MD, United States

Time filter

Source Type

San Mateo, CA, May 22, 2017 (GLOBE NEWSWIRE) -- Evidation Health today announces the results from a study examining the association between behavioral traits inferred from passive trackers and self-reported overall health, physical health, mental health and quality of life (QoL) at ISPOR.  ISPOR’s meeting is one of the world’s largest conferences for health economics and outcomes research, with this year’s meeting anticipated to draw more than 3,800 attendees, from 80+ countries. It is well known that behavioral factors can have a profound effect on health outcomes and perceived quality of life. This study extends prior research by quantifying the link between behavioral data, including step and sleep data from activity trackers, and perceived health and QoL in the general population. “Digital methods have allowed us to expand our understanding of real-world behaviors, and their impact on health outcomes, outside of the traditional clinical trial setting,” said Jessie Juusola, Ph.D., Head of Health Outcomes Research at Evidation Health and the senior author on the study. “The findings from this study will inform the design of future studies quantifying the impact of healthcare interventions on perceived quality of life among disease-specific populations.” The poster “Digital Trackers Show That High Intensity Exercising And Consistent Sleep Patterns Are Associated With Positive Self-Reported Health Status,” identified by code PHP223, will be displayed at ISPOR’s  22nd Annual International Meeting, from 8:30 a.m. to 2:00 p.m. EST today, with an author-led discussion on the 7000+ participant study beginning at 1:00 p.m. EST. Authors of the study include: Shefali Kumar, MPH, Health Outcomes Research Senior Associate, Thomas Quisel, BS, Principal Data Scientist, Luca Foschini, PhD, Chief Data Scientist and Jessie Juusola, PhD, Head of Health Outcomes Research from Evidation Health. Evidation Health helps healthcare companies quantify outcomes in the digital era, with real life data from connected patients. The company developed its Real Life Study Platform to accelerate and enhance outcomes research through large-scale virtualized pragmatic trials-- collecting novel digital signals and measuring the impact of digital health and traditional interventions far more efficiently than conventional approaches.  Evidation Health works across the healthcare ecosystem with top pharmaceutical companies, payers, providers, and digital healthcare companies. Evidation Health is a privately held company headquartered in San Mateo, CA. For more information, visit www.evidation.com. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/232ce178-5c9d-40fd-a042-59f17bfddbcf


SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (La Jolla), today announced positive top-line results from the ATHOS-3 (Angiotensin II for the Treatment of High-Output Shock) Phase 3 study of LJPC-501 (angiotensin II) in patients with catecholamine resistant hypotension (CRH). The analysis of the primary efficacy endpoint, defined as the percentage of patients achieving a pre-specified target blood pressure response, was highly statistically significant: 23% of the 158 placebo-treated patients had a blood pressure response compared to 70% of the 163 LJPC-501-treated patients (p<0.00001). In addition, a trend toward longer survival was observed: 22% reduction in mortality risk through day 28 [hazard ratio=0.78 (0.57-1.07), p=0.12] for LJPC-501-treated patients. Throughout the study, safety outcomes were followed by an independent Data Safety Monitoring Board (DSMB). The DSMB recommended that the study continue as originally planned. In this critically ill patient population: 92% of placebo-treated patients compared to 87% of LJPC-501-treated patients experienced at least one adverse event, and 22% of placebo-treated patients compared to 14% of LJPC-501-treated patients discontinued treatment due to an adverse event. In collaboration with the investigators, La Jolla plans to present and publish detailed results from the ATHOS-3 study later this year. ATHOS-3 was conducted under a Special Protocol Assessment with the U.S. Food and Drug Administration (FDA), in which the company and FDA agreed on the study design, study endpoints and study analyses. “ These study results support that angiotensin II, a molecule first synthesized by Dr. Irvine Page at the Cleveland Clinic, improves outcomes in distributive shock patients requiring high-dose catecholamines. Given the high mortality from this condition, it is important to offer physicians another potential treatment option,” said Daniel Sessler, M.D., the Michael Cudahy Professor and Chair of the Department of Outcomes Research at Cleveland Clinic. “ We are grateful to the patients, their families and the dedicated medical teams who contributed to this successful study,” said George F. Tidmarsh, M.D., Ph.D., president and chief executive officer of La Jolla. “ We also are very appreciative of the FDA’s advice and contributions in the development of LJPC-501 and look forward to meeting with the FDA to discuss our NDA submission planned for the second half of this year.” Conference Call at 8:30 a.m. EST on Monday, February 27, 2017 La Jolla will host a conference call and webcast at 8:30 a.m. EST (5:30 a.m. PST) on Monday, February 27, 2017. The conference call can be accessed by dialing 877-359-9508 for domestic callers and 224-357-2393 for international callers. Please provide the operator with the passcode 78311826 to join the conference call or click here for the webcast. A slide presentation accompanying today’s press release and the conference call may also be found on La Jolla’s website at www.ljpc.com under the investor relations section. An archive of the conference call and webcast will be available on La Jolla’s website for 30 days following the call. The ATHOS-3 study (https://www.ncbi.nlm.nih.gov/pubmed/28215131) was a multicenter, randomized, double-blind, placebo-controlled, Phase 3 clinical study of LJPC-501 in patients with catecholamine resistant hypotension. A total of 344 patients were randomized across nine countries, 321 of whom received study treatment and are included in the primary analysis. Patients were randomized 1:1 to receive either LJPC-501 or placebo on a background of standard-of-care vasopressors selected by the investigators. Randomized patients received their assigned treatment via continuous intravenous infusion. The primary efficacy endpoint was the percentage of patients with a mean arterial pressure (MAP) ≥ 75 mmHg or a 10 mmHg increase from baseline MAP at 3 hours following the initiation of study treatment without an increase in standard-of-care vasopressors. The study was conducted under a Special Protocol Assessment (SPA) agreed to with the U.S. Food and Drug Administration (FDA) in 2015. The SPA stipulates that a study of this size and design could provide sufficient safety and efficacy signals and an adequate evaluation of the risk/benefit to the patients to support FDA review and consideration for marketing approval. LJPC-501 is La Jolla’s proprietary formulation of synthetic human angiotensin II. Angiotensin II, the major bioactive component of the renin-angiotensin system, serves as one of the body’s central regulators of blood pressure. LJPC-501 is being developed for the treatment of patients with catecholamine resistant hypotension (CRH). LJPC-501 is the first synthetic human angiotensin II product candidate to be tested in a Phase 3 study. Catecholamine resistant hypotension (CRH) is a life-threatening syndrome in patients with distributive shock (dangerously low blood pressure with adequate cardiac function) who cannot achieve target mean arterial pressure (MAP) despite adequate fluid resuscitation and treatment with currently available vasopressors (catecholamines and/or vasopressin). There are approximately 500,000 distributive shock cases in the United States per year, an estimated 200,000 of which develop CRH. More than 50% of CRH patients die within 30 days. La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The company has several product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of synthetic human angiotensin II for the potential treatment of catecholamine resistant hypotension. LJPC-401 is La Jolla’s proprietary formulation of synthetic human hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is La Jolla’s next-generation gentamicin derivative program that is focused on the potential treatment of serious bacterial infections as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy. For more information on La Jolla, please visit www.ljpc.com. This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or the company’s future results of operations. These statements are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors, that may cause actual results to be materially different from those anticipated by the forward-looking statements. The company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in the company’s filings with the U.S. Securities and Exchange Commission (SEC), all of which are available free of charge on the SEC’s web site www.sec.gov. These risks include, but are not limited to, risks relating to: the timing of the NDA submission for LJPC-501 and prospects for approval of the NDA; risks that the full data set from the ATHOS-3 study will not be consistent with the top-line results of the study; risks relating to the scope of product labels (if approved) and potential market sizes, as well as the broader commercial opportunity; the anticipated timing for regulatory actions; the success of future development activities; potential indications for which the company’s product candidates may be developed; and the expected duration over which the company’s cash balances will fund its operations. Subsequent written and oral forward-looking statements attributable to the company or to persons acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth in the company’s reports filed with the SEC. The company expressly disclaims any intent to update any forward-looking statements.


News Article | February 22, 2017
Site: www.PR.com

SMi’s Paediatric Clinical Trials show returns to London for the 11th year on 20th-21st March 2017. London, United Kingdom, February 22, 2017 --( Through a series of interactive conference sessions, presentations and a workshop led by industry experts; the 2017 agenda will discuss current clinical trials, implementation, drug development, recruitment and retention, ethical issues and regulations. Key presentations not to be missed: - Bianca McDade, Director Regulatory Affairs, GSK - Tom Willgoss, Senior Outcomes Research Scientist, Patient-Centred Outcomes Research, Roche - Karl-Heinz Huemer, Scientific Committee Member and Expert, EMA, PDCO - Hernando Patino, Paediatric Drug Development Lead, Johnson & Johnson - Deborah Lee, VP Clinical Development, Insys Therapeutics - Andy Kenwright, Senior Statistical Scientist, Roche - Robert Kahn, Former Senior Safety Science Leader, Global Pediatric Oncology, Genentech Highlights for 2017: - Update from the EMA on the PDCO's 10 year review into paediatric investigation plans - Discuss clinical trial legislation in the EU and US - Review challenges in paediatric drug development for rare diseases - Optimise approaches to paediatric drug formulation to improve clinical success - Evaluate recruitment and retention - Discuss hot topic of data extrapolation In the lead up to the event SMi have released some pre-conference interviews with some of the speakers. For further insight into the topics being discussed at this year’s conference and an overall look into the paediatric trials field visit the download centre of the event website to access the 2017 speaker interview series. Interviews available to download include: Roche, Insys Therapeutics, Paediatric Research Consultancy, The Birmingham Children’s Hospital and Klausrose Consulting. Countries attending Paediatric Clinical Trials 2017 include: Australia, Austria, Belgium, Denmark, France, Germany, Netherlands, Spain, Switzerland, United Kingdom & USA. For those who are interested in attending register online at the event website www.paediatric-trials.co.uk/prcom Paediatric Clinical Trials 20-21 March 2017 Copthorne Tara Hotel, London, UK www.paediatric-trials.co.uk/prcom Sponsorship enquiries: Contact Alia Malick on: +44 (0) 20 7827 6168 or email amalick@smi-online.co.uk Group bookings: Contact Ameenah Begum on: +44 (0) 20 7827 6166 or email abegum@smi-online.co.uk About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk London, United Kingdom, February 22, 2017 --( PR.com )-- With just 4 weeks to go, registration will be closing soon for SMi’s Paediatric Clinical Trials 2017. The event will bring together Clinical Operations Leads and Heads of Clinical Trials to review the developments leading to the advancement of paediatric medicines.Through a series of interactive conference sessions, presentations and a workshop led by industry experts; the 2017 agenda will discuss current clinical trials, implementation, drug development, recruitment and retention, ethical issues and regulations.Key presentations not to be missed:- Bianca McDade, Director Regulatory Affairs, GSK- Tom Willgoss, Senior Outcomes Research Scientist, Patient-Centred Outcomes Research, Roche- Karl-Heinz Huemer, Scientific Committee Member and Expert, EMA, PDCO- Hernando Patino, Paediatric Drug Development Lead, Johnson & Johnson- Deborah Lee, VP Clinical Development, Insys Therapeutics- Andy Kenwright, Senior Statistical Scientist, Roche- Robert Kahn, Former Senior Safety Science Leader, Global Pediatric Oncology, GenentechHighlights for 2017:- Update from the EMA on the PDCO's 10 year review into paediatric investigation plans- Discuss clinical trial legislation in the EU and US- Review challenges in paediatric drug development for rare diseases- Optimise approaches to paediatric drug formulation to improve clinical success- Evaluate recruitment and retention- Discuss hot topic of data extrapolationIn the lead up to the event SMi have released some pre-conference interviews with some of the speakers. For further insight into the topics being discussed at this year’s conference and an overall look into the paediatric trials field visit the download centre of the event website to access the 2017 speaker interview series. Interviews available to download include: Roche, Insys Therapeutics, Paediatric Research Consultancy, The Birmingham Children’s Hospital and Klausrose Consulting.Countries attending Paediatric Clinical Trials 2017 include: Australia, Austria, Belgium, Denmark, France, Germany, Netherlands, Spain, Switzerland, United Kingdom & USA. For those who are interested in attending register online at the event website www.paediatric-trials.co.uk/prcomPaediatric Clinical Trials20-21 March 2017Copthorne Tara Hotel, London, UKwww.paediatric-trials.co.uk/prcomSponsorship enquiries: Contact Alia Malick on: +44 (0) 20 7827 6168 or email amalick@smi-online.co.ukGroup bookings: Contact Ameenah Begum on: +44 (0) 20 7827 6166 or email abegum@smi-online.co.ukAbout SMi Group:Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk Click here to view the list of recent Press Releases from SMi Group


News Article | February 15, 2017
Site: www.prweb.com

Medication nonadherence, e.g. patients not taking medication as prescribed or discontinuing before they finish the course, has been shown to seriously hurt health outcomes in neurology. One of the reasons for this may be financial barriers. Now, a new study published in ClinicoEconomics and Outcomes Research examines this further. A research team from Massachusetts General Hospital , set out to capture more accurate, specific and informative date on medication nonadherence in neurology in a study entitled “Patient-reported financial barriers to adherence to treatment in neurology.” The US team collected cross-sectional survey responses using an iPad as part of routine outpatient care in a neurology clinic over a three-month period. They merged this data with administrative sources of demographic and clinical information, insurance details for example, to form a fuller picture of how often and what the financial barriers to patients who fail to refill prescription medication. Almost 3,000 adults who came to the clinic between July and September 2015 participated in the survey. The mean age of participants was 56 years, and 54% were female. Participants were comparable to nonparticipants with respect to gender and ethnicity but more often identified English as their preferred language. Two-hundred-and-sixty-five respondents (9.8%) reported nonadherence that varied by condition. These patients were more frequently Hispanic, living alone, and preferred a language other than English. The study found that the magnitude of financial barriers to medication adherence appears to vary across neurological conditions and demographic characteristics. Corresponding author of the study, Dr Lidia Moura, said, “Our results suggest that one in ten of our patients with neurological problems have reported financial barriers to medication adherence. These findings are consistent with previous studies that found that trouble affording medications was the fourth leading reason for medication nonadherence among elderly patients. The study offers opportunities to improve outcomes in neurology patients through medication adherence and drive health policy in neurology.” She continued, “The study also suggests that while the overall level of poor adherence due to costs is limited, cost-related barriers to medication adherence appear to be concentrated among the most cognitively- and socioeconomically vulnerable patients. Multiple strategies are needed to prospectively identify these vulnerable patients and to alter prescribing practices to enhance affordability and thereby long-term efficacy.” Editor’s notes: The ClinicoEconomics and Outcomes Research journal is published by Dove Medical Press, a publisher of over 100 Open Access journals in medicine and the sciences. The ClinicoEconomics and Outcomes Research journal focuses on health technology assessment, pharmacoeconomics and outcomes research in the areas of diagnosis, medical devices, and clinical, surgical and pharmacological intervention. The economic impact of health policy and health systems organization also constitute important areas of coverage. The journal is headed up by Editor-in-Chief Professor Giorgio Colombo. ISSN: 1178-6981 It is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE).


News Article | February 15, 2017
Site: www.eurekalert.org

Though there is a growing armamentarium of medical therapies to treat neurological disease, patient adherence to taking the medication is critical to their effectiveness. Medication nonadherence, e.g. patients not taking medication as prescribed or discontinuing before they finish the course, has been shown to seriously hurt health outcomes in neurology. One of the reasons for this may be financial barriers. Now, a new study published in ClinicoEconomics and Outcomes Research examines this further. A research team from Massachusetts General Hospital set out to capture more accurate, specific and informative date on medication nonadherence in neurology in a study entitled "Patient-reported financial barriers to adherence to treatment in neurology." The US team collected cross-sectional survey responses using an iPad as part of routine outpatient care in a neurology clinic over a three-month period. They merged this data with administrative sources of demographic and clinical information, insurance details for example, to form a fuller picture of how often and what the financial barriers to patients who fail to refill prescription medication. Almost 3,000 adults who came to the clinic between July and September 2015 participated in the survey. The mean age of participants was 56 years, and 54% were female. Participants were comparable to nonparticipants with respect to gender and ethnicity but more often identified English as their preferred language. Two-hundred-and-sixty-five respondents (9.8%) reported nonadherence that varied by condition. These patients were more frequently Hispanic, living alone, and preferred a language other than English. The study found that the magnitude of financial barriers to medication adherence appears to vary across neurological conditions and demographic characteristics. Corresponding author of the study, Dr Lidia Moura, said "Our results suggest that one in ten of our patients with neurological problems have reported financial barriers to medication adherence. These findings are consistent with previous studies that found that trouble affording medications was the fourth leading reason for medication nonadherence among elderly patients. The study offers opportunities to improve outcomes in neurology patients through medication adherence and drive health policy in neurology." She continued, "The study also suggests that while the overall level of poor adherence due to costs is limited, cost-related barriers to medication adherence appear to be concentrated among the most cognitively- and socioeconomically vulnerable patients. Multiple strategies are needed to prospectively identify these vulnerable patients and to alter prescribing practices to enhance affordability and thereby long-term efficacy." The ClinicoEconomics and Outcomes Research journal is published by Dove Medical Press, a publisher of over 100 Open Access journals in medicine and the sciences. The ClinicoEconomics and Outcomes Research journal focuses on health technology assessment, pharmacoeconomics and outcomes research in the areas of diagnosis, medical devices, and clinical, surgical and pharmacological intervention. The economic impact of health policy and health systems organization also constitute important areas of coverage. The journal is headed up by Editor-in-Chief Professor Giorgio Colombo. ISSN: 1178-6981 It is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE).


KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Lori Michener, PhD, PT, ATC, SCS, FAPTA, a member of MedRisk’s International Scientific Advisory Board (ISAB), has been elected vice president of the Orthopaedic Section of the American Physical Therapy Association (APTA). ISAB is an elite panel of world-renowned specialists in physical medicine, diagnostic imaging and workers’ compensation who oversee all clinical aspects of MedRisk’s medical management programs. Dr. Michener is the director of clinical outcomes and research in the Division of Biokinesiology and Physical Therapy at the University of Southern California. She also oversees USC’s Clinical Biomechanics and Orthopedics Outcomes Research program, known as COOR, and is a professor in its Physical Therapy department. Her expertise is in musculoskeletal shoulder pain biomechanics, shoulder and cervical pain diagnosis and treatment, shoulder and cervical disorder clinical trial research, and the use of patient-rated outcomes measurement tools to assess health-related quality of life. Dr. Michener has served on several professional panels for such healthcare organizations as the American College of Occupational and Environmental Medicine and Agency for Healthcare Research and Quality as well as APTA and ISAB. MedRisk is the leader in physical rehabilitation and diagnostic imaging solutions for the workers’ compensation industry. Founded in 1994 and based in King of Prussia, Pa., MedRisk is accredited under URAC for utilization management and has successfully completed a SSAE 16 Type II examination. MedRisk’s programs deliver savings and operational efficiencies that are significantly greater than traditional programs. Customers include insurance carriers, self-insured employers, third-party administrators, state funds, and case management companies. To make a referral or obtain more information, visit www.medrisknet.com or call 800-225-9675.


The American Orthopaedic Foot & Ankle Society® (AOFAS) and M2S® proudly announce the launch of the Orthopaedic Foot & Ankle Outcomes Research Network (OFAR)®, a patient-reported outcomes data collection system.


ROSEMONT, Ill. and WEST LEBANON, N.H., Mar. 1, 2017 /PRNewswire-USNewswire/ -- The American Orthopaedic Foot & Ankle Society® (AOFAS) and M2S® proudly announce the launch of the Orthopaedic Foot & Ankle Outcomes Research Network (OFAR)®, a patient-reported outcomes data collection...


BETHLEHEM, PA--(Marketwired - Feb 15, 2017) - The appropriate use of parenteral nutrition, a topic of growing importance for treating critically ill patients, is the focus for the symposium sponsored by B. Braun Medical Inc. at this year's American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Clinical Nutrition Week. B. Braun will present Dr. Gordon S. Doig, a leading researcher in the area of early parenteral nutrition in critically ill patients, at the symposium for continuing education credits on Feb. 19 from 6:30 a.m. - 7:30 a.m. in Grand Ballroom 8A at the Marriott Orlando World Center in Orlando, Fla. The event will be preceded by a breakfast buffet at 6:00 a.m. Doig's research, which has been published in the Journal of the American Medical Association and ClinicoEconomics and Outcomes Research, concludes that the use of parenteral nutrition in critically ill patients with short-term, relative contraindications to enteral nutrition may result in improved patient outcomes and significantly reduce total cost of care. Doig is associate professor of intensive care at the University of Sydney and Royal North Shore Hospital, Sydney, Australia. B. Braun's response to help address malnutrition in the hospitalized and home care patient will be presented throughout Clinical Nutrition Week, Feb. 18-20. B. Braun representatives at booth #201 will be available to discuss the company's new parenteral nutrition program -- PN360. According to the December 2016 Healthcare Cost and Utilization Project (HCUP) statistical brief #218, malnutrition has been associated with longer and more costly hospital stays, as well as a greater likelihood of comorbidity and death among hospitalized patients. Malnutrition may also contribute to post hospital syndrome, described as "an acquired transient period of vulnerability" following hospitalization, which may dramatically increase the risk of readmission, the brief indicated. Also on Feb. 19, from 12:45 p.m. to 1:45 p.m., B. Braun will host a poster session in the exhibit hall on "Understanding the Incidence of Bloodstream Infections and Patient Outcomes by Type of Parenteral Nutrition Preparation Method." B. Braun's poster detailing the session will be on display starting at 6 p.m. on Feb.18. B. Braun also will showcase its new macro and micro APEX® compounding system at booth #201 for health care facilities that need in-house compounding capabilities, and its wide selection of amino acid formulations, standard solutions, and related additives, in containers that are not made with natural rubber latex, PVC or DEHP. About B. Braun B. Braun Medical Inc., a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the health care industry. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is headquartered in Bethlehem, Pa., and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap® and CAPS®. Globally, the B. Braun Group of Companies employs more than 56,000 employees in more than 60 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, visit www.BBraunUSA.com.


BETHLEHEM, PA--(Marketwired - Feb 15, 2017) - The appropriate use of parenteral nutrition, a topic of growing importance for treating critically ill patients, is the focus for the symposium sponsored by B. Braun Medical Inc. at this year's American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Clinical Nutrition Week. B. Braun will present Dr. Gordon S. Doig, a leading researcher in the area of early parenteral nutrition in critically ill patients, at the symposium on Feb. 19 from 6:30 a.m. - 7:30 a.m. in Grand Ballroom 8A at the Marriott Orlando World Center in Orlando, Fla. The event will be preceded by a breakfast buffet at 6:00 a.m. Doig's research, which has been published in the Journal of the American Medical Association and ClinicoEconomics and Outcomes Research, concludes that the use of parenteral nutrition in critically ill patients with short-term, relative contraindications to enteral nutrition may result in improved patient outcomes and significantly reduce total cost of care. Doig is associate professor of intensive care at the University of Sydney and Royal North Shore Hospital, Sydney, Australia. B. Braun's response to help address malnutrition in the hospitalized and home care patient will be presented throughout Clinical Nutrition Week, Feb. 18-20. B. Braun representatives at booth #201 will be available to discuss the company's new parenteral nutrition program -- PN360. According to the December 2016 Healthcare Cost and Utilization Project (HCUP) statistical brief #218, malnutrition has been associated with longer and more costly hospital stays, as well as a greater likelihood of comorbidity and death among hospitalized patients. Malnutrition may also contribute to post hospital syndrome, described as "an acquired transient period of vulnerability" following hospitalization, which may dramatically increase the risk of readmission, the brief indicated. Also on Feb. 19, from 12:45 p.m. to 1:45 p.m., B. Braun will host a poster session in the exhibit hall on "Understanding the Incidence of Bloodstream Infections and Patient Outcomes by Type of Parenteral Nutrition Preparation Method." B. Braun's poster detailing the session will be on display starting at 6 p.m. on Feb.18. B. Braun also will showcase its new macro and micro APEX® compounding system at booth #201 for health care facilities that need in-house compounding capabilities, and its wide selection of amino acid formulations, standard solutions, and related additives, in containers that are not made with natural rubber latex, PVC or DEHP. About B. Braun B. Braun Medical Inc., a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the health care industry. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is headquartered in Bethlehem, Pa., and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap® and CAPS®. Globally, the B. Braun Group of Companies employs more than 56,000 employees in more than 60 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, visit www.BBraunUSA.com.

Loading Outcomes Research collaborators
Loading Outcomes Research collaborators